| 2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P. |
 |
| 2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P. |
|
| 2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P. |
|
| 2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 |
Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251. |
|
| 2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P. |
|
| 2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD. |
|
| 2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286. |
|
| 2018-08-24 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor |
Cancer Science. 2018 Nov;109(11):3591-3601. |
|
| 2018-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients |
Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598. |
|
| 2018-06 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma |
Annals of Oncology. 2018 Jun;29(6):1402-1408. |
|
| 2018-06 |
The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152. |
|
| 2018-06 |
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153. |
|
| 2018-06 |
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150. |
|
| 2018-06 |
Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004. |
|
| 2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151. |
|
| 2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127. |
|
| 2018-05 |
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers |
Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556. |
|
| 2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204. |
|
| 2018-04 |
The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis |
Cancer Research and Treatment. 2018 Apr;50(2):562-574. |
|
| 2018-04 |
Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study |
Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093. |
|
| 2018-03 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use |
Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183. |
|
| 2018-03 |
Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy |
Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31. |
|
| 2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development |
OncoImmunology. 2018 Feb 1;7(5):Article number e1424612. |
|
| 2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460. |
|
| 2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459. |
|
